Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurocrine Biosciences Inc.

www.neurocrine.com

Latest From Neurocrine Biosciences Inc.

Deal Watch: Sanofi Further Opts Out Of CNS Tie-Up With Voyager

Sanofi returns two partnered assets to Voyager, further unraveling 2015 deal. Celgene drops Mereo cancer candidate ahead of merger with Bristol, while Ultragenyx and Arcturus expand their joint rare disease efforts.

Business Strategies Commercial

Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019

An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.

Financing Regenerative Medicine

Teva’s Ajovy Claims 28%-30% New Prescription Share In Competitive CGRP Race

The company said it has captured a roughly 28%-30% share of new prescriptions in the CGRP market with the initial launch of Ajovy, a key future growth driver to offset declining Copaxone sales.

Sales & Earnings Launches

Why Biogen/Eisai's Aducanumab Failure Is Not The End Of Amyloid Hypothesis

Biogen and Eisai still have multiple programs testing amyloid-targeting therapies in the treatment of Alzheimer's disease, but pressure for Biogen to focus its efforts elsewhere are mounting after the partners discontinued Phase III studies for aducanumab.

Clinical Trials Neurology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gynecological, Urological
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Neurocrine Biosciences Inc.
  • Senior Management
  • Kevin C Gorman, PhD, CEO
    Kyle Gano, PhD, Chief Bus. Dev. Officer
    Haig Bozigian, PhD, Chief Dev. Officer
    Dimitri Grigoriadis, PhD, Chief Research Officer
    Malcolm Lloyd-Smith , Chief Reg. Officer
    Christopher O'Brien, MD, CMO
  • Contact Info
  • Neurocrine Biosciences Inc.
    Phone: (858) 617-7600
    12780 El Camino Real
    San Diego, CA 92130
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register